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The Cost-Effectiveness of Vaccinating
against Lyme Disease
To the Editor: The recent article by Meltzer and
colleagues (1) is an important contribution to a
pertinent public health issue: who should receive
the newly licensed Lyme disease vaccine.
Answering this question is a daunting task,
given the scarcity of valid data. Estimates of the
spectrum and prevalence of the long-term
sequelae of Lyme disease remain controversial
(2-4). In generating their cost-effectiveness
model, Meltzer et al. examined the cost savings
involved in preventing three categories of classic
organ-specific Lyme disease sequelae (cardiovas-
cular, neurologic, and arthritic); however, they
did not take into account the potential cost
savings from preventing cases of a generalized
symptom complex known as post-Lyme syn-
drome, which includes persisting myalgia,
arthralgia, headache, fatigue, and neurocognitive
deficits. These generalized sequelae, which are
recognized by the National Institutes of Health
as late sequelae of Lyme disease, have been
found to persist for years after antibiotic therapy
(5,6). Two population-based retrospective cohort
studies (7,8) among Lyme disease patients whose
illness was diagnosed in the mid-1980s
determined that one third to half had clinically
corroborated post-Lyme syndrome symptoms
years after the initial onset of disease. Although
these studies were conducted 15 years ago, when
optimal antibiotic regimen guidelines were still
evolving, the estimated cost of averting these
often-disabling nonorgan-specific symptoms
should also be taken into account in estimated
detected in digestive tracts of flies exposed to
feces with oocysts. C. parvum oocysts were also
numerous on maggot and pupa surfaces;
approximately 150 and 320 oocysts were
recovered per maggot and pupa, respectively.
Wild-caught flies belonged to the families
Calliphoridae (96% of total flies), Sarcophagidae
(2%), and Muscidae (2%). An average of eight
flies was caught per trap, and more than 90% of
flies harbored C. parvum oocysts. The number of
trap-recovered C. parvum oocysts per fly was 2 to
246 (mean 73 oocysts per fly).
Synanthropic flies that breed in or come in
contact with a fecal substrate contaminated with
C. parvum oocysts can harbor these oocysts both
externally and internally and will mechanically
deposit them on other surfaces. Therefore,
synanthropic flies can serve as mechanical
vectors for C. parvum oocysts and under poor
sanitary conditions could be involved in the
transmission of human and animal
cryptosporidiosis. The biology and ecology of
synanthropic flies indicate that their potential
for mechanical transmission of C. parvum
oocysts can be high. The morphologic and AFS
and IFA staining characteristics of C. parvum
oocysts recovered from the exoskeletons of flies
and identified in their fecal spots suggest that
oocysts are still viable.
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sensitivity analyses of vaccine cost-effectiveness.
The cost of treating sequelae is weighted heavily
in the cost-effectiveness models presented by
Meltzer and colleagues, which adds importance
to considering post-Lyme syndrome. Neverthe-
less, we recognize the difficulty of this modeling,
especially in the absence of validated cost-of-
treatment data for these generalized symptoms.
A point of correction is that Meltzer et al.
erroneously cite one of these studies (7) to infer
that the long-term clinical sequelae of Lyme
disease lasted a mean of 6.2 years from the onset
of disease. In this retrospective study, Shadick
et al. evaluated 38 persons with a clinical history
of Lyme disease a mean of 6.2 years from the
onset of disease regardless of the presence of
persisting symptoms; 25 of these patients had no
residual symptoms at follow-up. To accurately
estimate the duration of clinical sequelae,
longitudinal evaluations of representative popu-
lations of Lyme disease patients will be required
because late manifestations have been demon-
strated months to years after diagnosis (9,10).
Dimitri Prybylski
University of Maryland School of Medicine,
Baltimore, Maryland, USA
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